| Literature DB >> 27806300 |
Hiroto Hatakeyama1, Sherry Y Wu1, Yasmin A Lyons1, Sunila Pradeep1, Wanqin Wang2, Qian Huang2, Karem A Court3, Tao Liu4, Song Nie4, Cristian Rodriguez-Aguayo5, Fangrong Shen1, Yan Huang1, Takeshi Hisamatsu1, Takashi Mitamura6, Nicholas Jennings1, Jeajun Shim7, Piotr L Dorniak1, Lingegowda S Mangala8, Marco Petrillo9, Vladislav A Petyuk4, Athena A Schepmoes4, Anil K Shukla4, Madeline Torres-Lugo3, Ju-Seog Lee7, Karin D Rodland4, Anna Fagotti10, Gabriel Lopez-Berestein11, Chun Li2, Anil K Sood12.
Abstract
Even though hyperthermia is a promising treatment for cancer, the relationship between specific temperatures and clinical benefits and predictors of sensitivity of cancer to hyperthermia is poorly understood. Ovarian and uterine tumors have diverse hyperthermia sensitivities. Integrative analyses of the specific gene signatures and the differences in response to hyperthermia between hyperthermia-sensitive and -resistant cancer cells identified CTGF as a key regulator of sensitivity. CTGF silencing sensitized resistant cells to hyperthermia. CTGF small interfering RNA (siRNA) treatment also sensitized resistant cancers to localized hyperthermia induced by copper sulfide nanoparticles and near-infrared laser in orthotopic ovarian cancer models. CTGF silencing aggravated energy stress induced by hyperthermia and enhanced apoptosis of hyperthermia-resistant cancers.Entities:
Keywords: CTGF; DOPC-liposome; copper sulfide nanoparticle; hyperthermia; ovarian cancer; thermosensitivity
Mesh：
Substances：
Year: 2016 PMID： 27806300 PMCID： PMC5123842 DOI： 10.1016/j.celrep.2016.10.020
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423